What is the current Viral Gene Therapy market size?

The current Viral Gene Therapy market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Viral Gene Therapy market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Viral Gene Therapy market?

Key drivers include rising genetic disorders and advancements in gene editing technologies.

What are the major challenges facing the Viral Gene Therapy market?

Challenges include high development costs, regulatory hurdles, and limited awareness.

Which regions are leading the Viral Gene Therapy market?

North America and Europe are currently leading, due to strong healthcare infrastructure.

Who are the top companies in the Viral Gene Therapy market?

Top companies include Biogen, Gilead Sciences, and Spark Therapeutics, driving innovation.

What are the future opportunities in the Viral Gene Therapy market?

Future opportunities include emerging markets, new indications, and combination therapies.

How is technology impacting the Viral Gene Therapy market?

Advances in CRISPR technology and gene editing are transforming the future outlook.

What is the current regulatory landscape for Viral Gene Therapy?

Regulatory frameworks are evolving, with a focus on safety, efficacy, and patient access.

What does the future outlook of the Viral Gene Therapy market look like?

The future outlook is promising, with growing demand and increasing investment in research.

Viral Gene Therapy Market Comprehensive Report: 200+ Pages | 2026–2034

Viral Gene Therapy by Application (Metabolic Diseases, Cardiovascular Diseases, Muscular Diseases, Hematologic Diseases, Ophthalmologic Diseases, Infectious Diseases, Others), by Types (Integrating Viral Vectors, Non-Integrating Viral Vectors), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 19.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 19.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Viral Gene Therapy Market Overview

The Viral Gene Therapy market refers to the industry focused on developing and commercializing gene therapies that utilize viral vectors to treat or prevent diseases. As a rapidly evolving field, the Viral Gene Therapy market size is estimated to be around $2.5 billion in 2025, with a growth outlook that is highly promising due to its potential to revolutionize the treatment of genetic disorders and other diseases. The market forecast suggests a significant expansion, driven by advancements in technology, increasing investment, and a rising demand for innovative treatments. The industry expansion is expected to be fueled by a compound annual growth rate (CAGR) of around 20%, driven by key forces such as technology shifts, regulatory support, and changing consumer behavior.

Loading chart…

The largest region in the Viral Gene Therapy market is currently North America, driven by the presence of major pharmaceutical companies and research institutions. The fastest-growing region is expected to be Asia-Pacific, driven by increasing investment in gene therapy research and development, as well as a growing demand for innovative treatments. The market is expected to be shaped by key forces such as technology shifts, regulatory support, and changing consumer behavior, with companies focusing on developing more effective and safe viral vectors, and regulators providing support for the development of new treatments. Overall, the Viral Gene Therapy market is poised for significant growth, driven by its potential to revolutionize the treatment of genetic disorders and other diseases.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	48.91 billion
Growth rate	CAGR of 19.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza; Biogen; Catalent; Gilead Sciences; Sarepta Therapeutics; Novartis; Amgen; Ionis Pharmaceuticals; Spark Therapeutics; Shanghai Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Viral Gene Therapy market is poised for significant growth, driven by advancements in technology and increasing demand for innovative treatments. The Viral Gene Therapy market size is expected to expand substantially, with a promising growth forecast that underscores the potential for investment and development in this sector.

Growth Drivers2 items

Advances in viral vector technology have improved the safety and efficacy of gene therapy treatments, driving adoption and fueling market growth.

Increasing investments in research and development, coupled with favorable regulatory environments, are contributing to the expansion of the Viral Gene Therapy market.

Restraints2 items

High development costs and complex manufacturing processes are significant barriers to entry for new players, limiting competition and potentially stifling innovation in the Viral Gene Therapy market.

Stringent regulatory requirements and the need for long-term safety and efficacy data may hinder the approval and commercialization of new gene therapies, impacting the growth forecast.

Opportunities2 items

The increasing prevalence of genetic disorders and the growing demand for personalized medicines are creating new opportunities for Viral Gene Therapy market players to develop targeted treatments.

Collaborations between industry players, academia, and research institutions can facilitate the development of novel gene therapies, driving growth and innovation in the sector.

Challenges2 items

Ensuring the accessibility and affordability of gene therapies, particularly in low- and middle-income countries, remains a significant challenge for the Viral Gene Therapy market.

Managing the potential risks and side effects associated with gene therapies, such as immune responses and insertional mutagenesis, is crucial for maintaining public trust and confidence in these treatments.

Market Segmentation

Loading chart…

The Application segment in the Viral Gene Therapy market refers to the various diseases or conditions that viral gene therapies are used to treat. This segment is crucial in determining the overall market size, as different applications have distinct patient populations, treatment protocols, and reimbursement landscapes. The Viral Gene Therapy segmentation by application includes subtypes such as oncology, inherited disorders, and infectious diseases, each contributing to the market size in varying proportions. Understanding the application segment is essential for market players to develop targeted therapies and business strategies.

The Types segment in the Viral Gene Therapy market encompasses the different viral vectors used to deliver genetic material into cells. This segment is vital in understanding the market taxonomy, as various viral vectors have distinct characteristics, advantages, and limitations. The subtypes under this segment include adenoviral vectors, lentiviral vectors, and adeno-associated viral vectors. Each subtype has its own market share, driven by factors such as efficacy, safety, and production costs. Analyzing the types segment helps market players to identify opportunities for innovation and investment in the Viral Gene Therapy market.

Viral Gene Therapy Segmentation Breakdown11 items

Application

Metabolic Diseases

Cardiovascular Diseases

Muscular Diseases

Hematologic Diseases

Ophthalmologic Diseases

Infectious Diseases

Others

Types

Integrating Viral Vectors

Non-Integrating Viral Vectors

Regional Insights

Loading chart…

The Viral Gene Therapy market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of gene therapies, favorable policies, and significant investments in the region's infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. Europe's growth is driven by policies supporting gene therapy research, a strong ecosystem, and increasing adoption rates. Asia Pacific's growth is fueled by investments in infrastructure, a large and growing demographics base, and favorable policies. Latin America's growth is driven by increasing adoption rates, improving infrastructure, and growing demographics. The Middle East & Africa region is expected to witness moderate growth, driven by increasing investments and improving infrastructure.

The regional forecast indicates that the Viral Gene Therapy market will experience significant growth in the coming years, driven by increasing adoption rates, favorable policies, and growing demographics. As the market continues to evolve, it is essential to monitor regional trends and market growth to capitalize on emerging opportunities.

Competitive Landscape

The Viral Gene Therapy market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. The Viral Gene Therapy competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies concentrate on pricing and distribution.

Common strategies employed by companies in this market include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adopting various strategies to stay competitive, as outlined below:

Lonza: regional expansion

Biogen: innovation pipeline

Catalent: vertical integration

Gilead Sciences: premium pricing

Sarepta Therapeutics: local manufacturing

Novartis: OEM tie-ups

Key Viral Gene Therapy Companies13 items

Lonza

Biogen

Catalent

Gilead Sciences

Sarepta Therapeutics

Novartis

Amgen

Ionis Pharmaceuticals

Spark Therapeutics

Shanghai Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Market Ecosystem

The Viral Gene Therapy ecosystem encompasses a complex network of participants, from upstream technology providers to downstream end users. The ecosystem can be divided into three main segments: upstream, midstream, and downstream. Upstream participants, such as technology providers and suppliers, create and supply the foundational components and technologies. Midstream participants, including integrators and channels, develop and deliver the gene therapy products. Downstream participants, comprising end users and channels, receive and utilize the final products. Value is created and captured throughout this ecosystem as participants interact and exchange goods, services, and information.

Raw material/component suppliers — provide essential materials

Technology providers — develop gene editing tools

OEMs / manufacturers — produce gene therapy products

System integrators / EPCs — design and develop delivery systems

Distributors / channel partners — deliver products to end users

Regulators/standards bodies — establish and enforce safety standards

End users / buyers — receive and utilize gene therapy products

In the Viral Gene Therapy ecosystem, control points are primarily held by regulators and standards bodies, as they influence adoption through safety and efficacy approvals. Dependency risks arise from input constraints, such as access to high-quality raw materials, and standards, including those related to manufacturing and delivery. Switching costs and partnerships can also impact the ecosystem, particularly in cases where companies invest heavily in specific technologies or collaborations. Furthermore, the ecosystem may differ by region due to variations in regulatory frameworks, healthcare systems, and patient needs, highlighting the importance of a thorough value chain analysis to navigate these complexities.

Recent Industry Insights

The Viral Gene Therapy industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have driven innovation in the field. Notable mergers and acquisitions have also taken place, with key players expanding their portfolios and strengthening their positions in the market. Furthermore, several product and technology launches have been announced, showcasing advancements in viral vector design and gene editing technologies.

Regulatory changes have also impacted the Viral Gene Therapy industry, with updated guidelines and approvals facilitating the development and commercialization of gene therapies. Additionally, there has been a shift in consumer and enterprise trends, with increased focus on personalized medicine and rare disease treatments. Funding rounds and expansions have been secured by several companies, enabling them to advance their pipelines and accelerate the development of viral gene therapies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Viral Gene Therapy market outlook. The market attractiveness is moderate to high, driven by increasing demand for innovative treatments. Competitive intensity is expected to rise as more players enter the market. The long-term outlook is promising, with potential applications in various therapeutic areas. The innovation landscape is rapidly evolving, with advancements in vector technologies and gene editing tools. However, the demand–supply balance may be affected by regulatory challenges and manufacturing capacity constraints. Key risk factors include safety concerns, high development costs, and reimbursement uncertainties. Overall, the Viral Gene Therapy market is poised for growth, but stakeholders must navigate these challenges to capitalize on its potential.

11 items

1. Executive Summary

2. Viral Gene Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Viral Gene Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Viral Gene Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Metabolic Diseases

6.1.2. Cardiovascular Diseases

6.1.3. Muscular Diseases

6.1.4. Hematologic Diseases

6.1.5. Ophthalmologic Diseases

6.1.6. Infectious Diseases

6.1.7. Others

6.2. Global Viral Gene Therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Integrating Viral Vectors

6.2.2. Non-Integrating Viral Vectors

6.3. Global Viral Gene Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Viral Gene Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Viral Gene Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Viral Gene Therapy Market Competition by Key Manufacturers

8.1. Global Viral Gene Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Viral Gene Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Lonza

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Biogen

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Catalent

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Gilead Sciences

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sarepta Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Novartis

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Amgen

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Ionis Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Spark Therapeutics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Shanghai Sunway Biotech

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. SIBIONO

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. AnGes

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Orchard Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Viral Gene Therapy Market

Figure 4: Global Viral Gene Therapy Market: Drivers

Figure 5: Global Viral Gene Therapy Market: Challenges

Figure 6: Global Viral Gene Therapy Market: Trends

Figure 7: Global Viral Gene Therapy Market: Opportunity

Figure 8: Global Viral Gene Therapy Market: Restraint

Figure 9: Global Viral Gene Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Viral Gene Therapy Market Value (USD Million) By Region

Figure 15: Global Viral Gene Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Viral Gene Therapy Market Value (USD Million) By Region

Figure 23: Global Viral Gene Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Viral Gene Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Viral Gene Therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Viral Gene Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Viral Gene Therapy Market Value (USD Million) By Region

Table 10: Global Viral Gene Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Viral Gene Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Viral Gene Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Viral Gene Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Lonza Basic Information And Sales Area

Table 31: Lonza. Products Portfolio

Table 32: Biogen Basic Information And Sales Area

Table 33: Biogen. Products Portfolio

Table 34: Catalent Basic Information And Sales Area

Table 35: Catalent. Products Portfolio

Table 36: Gilead Sciences Basic Information And Sales Area

Table 37: Gilead Sciences. Products Portfolio

Table 38: Sarepta Therapeutics Basic Information And Sales Area

Table 39: Sarepta Therapeutics. Products Portfolio

Table 40: Novartis Basic Information And Sales Area

Table 41: Novartis. Products Portfolio

Table 42: Amgen Basic Information And Sales Area

Table 43: Amgen. Products Portfolio

Table 44: Ionis Pharmaceuticals Basic Information And Sales Area

Table 45: Ionis Pharmaceuticals. Products Portfolio

Table 46: Spark Therapeutics Basic Information And Sales Area

Table 47: Spark Therapeutics. Products Portfolio

Table 48: Shanghai Sunway Biotech Basic Information And Sales Area

Table 49: Shanghai Sunway Biotech. Products Portfolio

Table 50: SIBIONO Basic Information And Sales Area

Table 51: SIBIONO. Products Portfolio

Table 52: AnGes Basic Information And Sales Area

Table 53: AnGes. Products Portfolio

Table 54: Orchard Therapeutics Basic Information And Sales Area

Table 55: Orchard Therapeutics. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Viral Gene Therapy Market Value (USD Million) By Region

Table 61: Global Viral Gene Therapy Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Viral Gene Therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	48.91 billion
Growth rate	CAGR of 19.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza; Biogen; Catalent; Gilead Sciences; Sarepta Therapeutics; Novartis; Amgen; Ionis Pharmaceuticals; Spark Therapeutics; Shanghai Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in viral vector technology have improved the safety and efficacy of gene therapy treatments, driving adoption and fueling market growth.

Increasing investments in research and development, coupled with favorable regulatory environments, are contributing to the expansion of the Viral Gene Therapy market.

Restraints2 items

Stringent regulatory requirements and the need for long-term safety and efficacy data may hinder the approval and commercialization of new gene therapies, impacting the growth forecast.

Opportunities2 items

Collaborations between industry players, academia, and research institutions can facilitate the development of novel gene therapies, driving growth and innovation in the sector.

Challenges2 items

Ensuring the accessibility and affordability of gene therapies, particularly in low- and middle-income countries, remains a significant challenge for the Viral Gene Therapy market.

Market Segmentation

Loading chart…

Viral Gene Therapy Segmentation Breakdown11 items

Application

Metabolic Diseases

Cardiovascular Diseases

Muscular Diseases

Hematologic Diseases

Ophthalmologic Diseases

Infectious Diseases

Others

Types

Integrating Viral Vectors

Non-Integrating Viral Vectors

Regional Insights

Loading chart…

Competitive Landscape

Lonza: regional expansion

Biogen: innovation pipeline

Catalent: vertical integration

Gilead Sciences: premium pricing

Sarepta Therapeutics: local manufacturing

Novartis: OEM tie-ups

Key Viral Gene Therapy Companies13 items

Lonza

Biogen

Catalent

Gilead Sciences

Sarepta Therapeutics

Novartis

Amgen

Ionis Pharmaceuticals

Spark Therapeutics

Shanghai Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Market Ecosystem

Raw material/component suppliers — provide essential materials

Technology providers — develop gene editing tools

OEMs / manufacturers — produce gene therapy products

System integrators / EPCs — design and develop delivery systems

Distributors / channel partners — deliver products to end users

Regulators/standards bodies — establish and enforce safety standards

End users / buyers — receive and utilize gene therapy products

Recent Industry Insights

Analyst Overview

Table of Contents